According to previous research, we found that a variety of factors may affect the efficacy of immune checkpoint inhibition therapy, including mutation or neoantigen load, the level of cytotoxic T cell infiltration, PD-L1 levels, defective antigen presentation, defective mismatch repair, interferon signaling, tumor aneuploidy, and gut microbes. This evidence concerns the gene CD274 and neoplasm.